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Abstract:  The  goal  of  the  present  work  was  to  study  the  feasibility  of  
10-hydroxycamptothecin (HCPT) nanoparticle preparation using supercritical antisolvent 
(SAS) precipitation. The influences of various experimental factors on the mean particle 
size  (MPS)  of  HCPT  nanoparticles  were  investigated.  The  optimum  micronization 
conditions are determined as follows: HCPT solution concentration 0.5 mg/mL, the flow 
rate  ratio  of  CO2  and  HCPT  solution  19.55,  precipitation  temperature  35  °C   and 
precipitation pressure 20 MPa. Under the optimum conditions, HCPT nanoparticles with a 
MPS of 180 ±  20.3 nm were obtained. Moreover, the HCPT nanoparticles obtained were 
characterized by Scanning electron microscopy, Dynamic light scattering, Fourier-transform 
infrared spectroscopy, High performance liquid chromatography-mass spectrometry, X-ray 
diffraction  and  Differential  scanning  calorimetry  analyses.  The  physicochemical 
characterization results showed that the SAS process had not induced degradation of HCPT. 
Finally, the dissolution rates of HCPT nanoparticles were investigated and the results proved 
that there is a significant increase in dissolution rate compared to unprocessed HCPT. 
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1. Introduction  
10-Hydroxycamptothecin (HCPT) (Figure 1), one of the natural camptothecin analogues, has been 
shown to have a broad spectrum of antitumor activity against breast, colon, lung, and ovarian cancers 
in  clinical  practice.  More  importantly,  HCPT  was  shown  to  be  more  potent  and  less  toxic  than 
camptothecin(CPT)  in  experiments  on  animals  and  in  human  clinical  evaluations,  mainly  in  
China [1,2]. However, due to its poor solubility in water or in physiologically acceptable organic 
solvents and in vitro and in vivo instability, clinical practical use of HCPT is limited [3]. The earlier 
clinical trials using its highly water-soluble sodium salt, HCPT-Na
+, which was the product of opening 
the lactone ring of HCPT, showed minimal anticancer activity and several unpredictable side effects 
such  as  myelosuppression,  hemorrhagic  cystitis,  diarrhea,  nausea,  vomiting,  and  dermatitis.  The 
lactone form is a more effective inhibitor of topoisomerase I compared to the carboxylate form, which 
has much lower anti-tumor activity [4]. Therefore, it is of great significance in developing the high 
performance delivery systems for the insoluble lactone form 10-HCPT. Recently, some novel delivery 
systems  of  HCPT  have  been  reported,  such  as  nanosuspensions  [5],  prodrugs  [6–9],  
nanoparticles  [10,11],  microspheres  [12–14],  niosomes  [3],  emulsions  [15]  and  polymeric  micelle 
systems  [16,17].  Among  these  tested  approaches,  nanosuspensions  system,  a  sub-micro  colloidal 
dispersion system, is considered as one of the most promising methods because of its characteristics in 
drug loading, release, delivery, stability and various options for administration, such as oral, parenteral, 
ocular and pulmonary pathways [18]. Production technologies of nanosuspensions currently used are 
pearl milling and high-pressure homogenization either in water or alternatively in mixtures of water 
with  water  miscible  liquids  or  non-aqueous  media,  such  as  liquid  polyethylene  glycols  or  oils. 
Supercritical antisolvent (SAS) is a new micronization technology that has been developed in recent 
years. It is suitable to prepare nanocrystals of drugs or biologically active substances because of their 
low temperature and inertia. Until now, many bioactive materials have been successfully processed 
into nanocrystals [19–24]. 
However,  no  report  has  been  carried  out  on  the  micronization  of  HCPT  using  SAS  process. 
Therefore, the aims of this work are to study the feasibility of HCPT nanoparticle preparation by SAS 
process and to evaluate the SAS process factors which influence the mean particle size (MPS) of 
HCPT  nanoparticles.  The  effects  of  concentration  of  HCPT  solution,  precipitation  temperature, 
precipitation pressure and drug solution flow rate on the MPS of HCPT nanoparticles were studied by 
a  four-factor,  four-level  OAD  with  an  OA16  (4
5)  matrix.  Moreover,  characterization  of  HCPT 
nanoparticles  was  analyzed  by  SEM,  DLS,  FTIR,  LC-MS,  XRD  and  DSC  with  the  purpose  of 
developing  a  suitable  drug  delivery  system  of  cancer  chemotherapy,  nanosuspension  of  
close-ring HCPT. Int. J. Mol. Sci. 2011, 12                       
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Figure 1. Molecular structure of 10-hydroxycamptothecin (HCPT). 
 
2. Experimental Section 
2.1. Materials 
10-HCPT (98.5% purity) was obtained from Zhejiang Hisun Pharmaceutical Co. Ltd (PR China). 
High purity CO2（99.99% purity）was purchased from Liming Gas Company of Harbin (PR China). 
Dimethyl sulfoxide (DMSO, 98.5% purity) was purchased from Sigma Aldrich. All solutions used in 
HPLC analysis were of HPLC grade and filtered using a 0.22 µm membrane filter (YDHITECH, 
China) with a filtration system (SHB-III, China). 
2.2. Apparatus and Supercritical Anti-Solvent (SAS) Process 
The schematic of SAS  process is shown in  Figure 2. The apparatus  consists of  a precipitation 
chamber  and  a  gas-liquid  separation  chamber.  The  CO2  is  cooled  with  a  cooler  before  being 
compressed by a liquid pump and the pressure is controlled by a back pressure regulator. Afterwards, 
the CO2 is pre-heated in a heat exchanger and enters into the precipitation chamber. Simultaneously, 
the solution is pumped, heated and fed to the 1000 mL precipitation chamber through a stainless steel 
nozzle.  This  nozzle  is  located  in  a  distinct  inlet  point  from  the  CO2,  but  also  in  the  top  of  the 
precipitation chamber. A stainless steel frit vessel of 200 nm was put into the precipitation chamber to 
collect the micronized particles and to let the SC–CO2/organic solvent mixture pass through. The flow 
rate of the mixture that leaves the precipitator is controlled by a valve located between the precipitation 
chamber  and  the  gas-liquid  separation  chamber.  Here  the  mixture  undergoes  a  decompression 
(pressure < 5 MPa) to induce the separation of the CO2 from the organic solvent. Further information 
and a schematic representation of the apparatus have been given elsewhere [25]. 
An SAS experiment begins by delivering supercritical CO2 to the precipitation chamber until the 
desired pressure is reached. CO2 steady flow of 8.5 kg/h is  established; then pure DMSO is  sent 
through  the  liquid  pump  to  the  precipitation  chamber  with  the  aim  of  obtaining  steady  state 
composition conditions during the HCPT precipitation. At this point, the flow of the pure DMSO is 
stopped and the HCPT/DMSO liquid solution is delivered through the nozzle of 150 μm. Once injected 
the fixed quantity of HCPT/DMSO solution, the liquid pump is stopped. However, supercritical CO2 
continues to flow for 30 min to wash the stainless steel frit vessel of 200 nm from the residual content 
of liquid solubilized in the supercritical antisolvent. If the final purge with pure CO2 is not performed, 
DMSO condenses during the depressurization and redissolves the micronized HCPT. Int. J. Mol. Sci. 2011, 12                       
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2.3. Optimization of SAS Process 
An orthogonal OA16 (4)
5 test design was used to investigate the optimal micronized condition of 
HCPT. The SAS experiment was carried out with 4 factors and 4 levels, namely: concentration of 
HCPT  solution  (0.5,  1.5,  3.0,  5.0  mg/mL),  drug  solution  flow  rate  (3.3,  6.6,  9.9,  13.2  mL/min), 
precipitation temperature (35, 46, 57, 68 °C ) and precipitation pressure (10, 15, 20, 25 MPa). The 
range of each factor level was based on the results of preliminary experiments. The mean particle size 
(MPS) of micronized HCPT (nm) was the dependent variable. The micronized HCPT obtained from 
the above 16 tests (Table 1) was operated following the method in the Section 3.2. 
Figure 2. Schematic illustration of the supercritical antisolvent (SAS) experimental apparatus. 
 
1. CO2 cylinder; 2. 14, 15, 19, 21, 23, 24, 26 and 27. Valves; 3. Check valve; 4. CO2 
cooler; 5. Liquid solution supply; 6. Liquid pump; 7 and 9. Flow meter; 8. CO2 pump;  
10, 13 and 20. Heat exchangers; 11, 12 and 25. Filters; 16. Nozzle; 17. Stainless steel frit 
vessel of 200 nm; 18. Precipitation chamber; 22. Gas-liquid sepatation chamber. 
2.4. Physicochemical Properties of HCPT Nanoparticles 
2.4.1. Research of the Morphology 
The morphology analysis of HCPT particles was carried out using SEM (Quanta 200, FEI). The 
samples were prepared by direct deposition of the powders onto a carbon tape placed on the surface of an 
aluminium stub. Before analysis, the samples were coated with gold for 4 min using a sputter coater. 
2.4.2. Dynamic Light Scattering (DLS) 
Micronized HCPT was suspended in filtered pure water and special cares were taken to eliminate 
dust  and  to  avoid  the  aggregation  of  particles.  The  water  was  pre-saturated  with  HCPT  to  avoid 
dissolution of the micronized particles. The suspension was analyzed in DLS (ZetaPALS, Brookhaven 
Instruments). Every measurement was repeated at least three times.  Int. J. Mol. Sci. 2011, 12                       
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2.4.3. FTIR Analysis 
The HCPT particles were diluted with KBr mixing powder at 1% and separately pressed to obtain 
self-supporting disks. The FTIR spectrum was obtained by IRAffinity-1 (SHIMADZU, Jepan) and 
recorded in the wave number range of 4000–500 cm
−1 at a resolution of 4 cm
−1. 
2.4.4. LC-MS Analysis 
The HCPT particles were dissolved in ethanol and LC-MS was obtained by analyst 1.4 of AB API 
3000 (USA). The mass spectrometer was operated in positive ion mode. 
2.4.5. XRD Analysis 
10 mg samples of HCPT particles, forming a weighted dispersion on a glass slide, were evaluated 
using  an  X-ray  powder  diffractometer  (Philips,  Xpert-Pro,  The  Netherlands).  The  samples  were 
irradiated using a Cu target tube at 30 mA and 50 kV. The samples were filled to the same depth inside 
the  sample  holder  by  leveling  with  a  spatula.  The  scanning  rate  (5°   min.)  was  constant  for  all  
XRD analysis. 
2.4.6. DSC Analysis 
Thermal analysis was carried out using DSC (TA instruments, model DSC 204) for HCPT particles. 
All thermal analyses were performed in an inert atmosphere (N2). Analysis was performed for 5.0 mg 
samples at a temperature heating rate of 5 °C /min and a temperature range of 20–265 °C . 
2.4.7. Dissolution Studies in Vitro 
100  mg  sample  was  added  to  a  500  mL  dissolution  medium  (6.4  g  Na2HPO4,  12H2O;  0.6  g 
KH2PO4; 5.85 g NaCl in 1000 mL distilled water; pH 7.4). Bath temperature and paddle speed were set 
at 37 ±  0.5 °C  and 100 rpm. At selected periods of 5, 10, 15, 30, 45, 60 and 120 min, 2 mL aliquots 
were  withdrawn  without  media  replacement,  filtered,  and  analyzed  using  reversed-phase  HPLC 
(waters) at λ = 266 nm. The data was expressed as a mean value ±  S.D (n = 6). The percentage of 
cumulated dissolution was defined as the sum of the mass of dissolved HCPT at time t, divided by the 
mass of added HCPT (100 mg). The dissolution profiles were plotted as the percentage of cumulated 
dissolution versus incubation time. 
Filtered samples were appropriately diluted with methanol and assayed for HCPT concentration by 
HPLC. Chromatographic analyses were performed on a waters HPLC system consisting of a pump 
(Model  1525),  an  auto-sampler  (Model  717  plus),  UV  detector  (Waters  2487  Dual  λ  Absorbance 
Detector). The C18 reverse phase column (Diamonsil, μm, 4.6 mm ×  250 mm, Dikma Technologies) 
was  used  at  room  temperature.  The  mobile  phase  consisted  of  70%  acetonitrile  delivered  at  
1.0 mL/min. The injection volume was 10 μL. The signal was monitored at 266 nm. Int. J. Mol. Sci. 2011, 12                       
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3. Results and Discussion  
3.1. Optimization Study 
The first step in the SAS micronization process is to optimize the operating conditions to obtain a 
minimum MPS of micronized HCPT. Since various parameters potentially affect the micronization 
process, the optimization of the experimental conditions is a critical step in developing an SAS method. 
In fact, the concentration of drug solution, precipitation temperature, precipitation pressure and drug 
solution flow rate are generally considered the most important factors that affect the MPS of HCPT. 
The investigated levels of each factor were selected depending on the preliminary experiment results 
of the single-factor. The optimization of the suitable operating conditions in SAS can be carried out 
step  by  step  or  by  using  an  experimental  design.  In  the  present  study,  all  selected  factors  were 
examined using an orthogonal OA16 (4
5) test design. The total evaluation index was used to analyse by 
statistical methods. The analysis results of orthogonal test, performed by statistical software Design 
Expert 7.0, are presented in Table 1. Table 2 lists the data of the analysis of variance (ANOVA) table 
of  this  experiment.  The  results  of  experiments  presented  in  Table  2  indicate  that  the  MPS  of 
micronization HCPT varied between 210.5 and 900.7 nm. The maximum MPS was found for trial 16 
and the lowest for trial 2. The factors influence the MPS of micronization HCPT were listed in a 
decreasing order as follows: A > C > B > D according to the R value. So, the minimum MPS of 
micronization  HCPT  was  obtained  when  the  concentration  of  HCPT  solution,  precipitation 
temperature, precipitation pressure and drug solution flow rate were A1B1C3D2 (0.5 mg/mL, 35 °C ,  
20 MPa and 6.6 mL/min), respectively. Through a confirmatory test, smaller micronized HCPT was 
obtained, with a MPS of 180 ±  20.3 nm. 
Table 1. Orthogonal array design matrix L16 (4)
5 and experimental results. 
Trial No.  A  B  C  D  Error  MPS (nm) ±  SD 
            (n = 3) 
1  1 (0.5)  1 (35)  1 (10)  1 (3.3)  1  381.2 
2  1 (0.5)  2 (46)  2 (15)  2 (6.6)  2  210.5 
3  1 (0.5)  3 (57)  3 (20)  3 (9.9)  3  350.0 
4  1 (0.5)  4 (68)  4 (25)  4 (13.2)  4  424.8 
5  2 (1.5)  1 (35)  2 (15)  3 (9.9)  4  409.4 
6  2 (1.5)  2 (46)  1 (10)  4 (13.2)  3  458.3 
7  2 (1.5)  3 (57)  4 (25)  1 (3.3)  2  437.9 
8  2 (1.5)  4 (68)  3 (20)  2 (6.6)  1  446.0 
9  3 (3.0)  1 (35)  3 (20)  4 (13.2)  2  350.6 
10  3 (3.0)  2 (46)  4 (25)  3 (9.9)  1  428.2 
11  3 (3.0)  3 (57)  1 (10)  2 (6.6)  4  752.8 
12  3 (3.0)  4 (68)  2 (15)  1 (3.3)  3  641.1 
13  4 (5.0)  1 (35)  4 (25)  2 (6.6)  3  402.9 
14  4 (5.0)  2 (46)  3 (20)  1 (3.3)  4  474.5 
15  4 (5.0)  3 (57)  2 (15)  4 (13.2)  1  720.6 
16  4 (5.0)  4 (68)  1 (10)  3 (9.9)  2  900.7 
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Table 1. Cont. 
Trial No.  A  B  C  D  Error  MPS (nm) ±  SD 
            (n = 3) 
K1
a  341.6  386.0  623.3  483.7  494.0   
K2  437.9  392.9  495.4  453.1  475.0   
K3  543.2  565.3  405.3  522.1  463.1   
K4  624.7  603.2  423.5  488.6  515.4   
R
b  283.1  217.1  218.0  69.0  52.3   
Optimal 
level 
A1  B1  C3  D2     
A,  Concentration  of  HCPT  solution  (mg/mL);  B,  Precipitation  temperature  (°C );  C,  Precipitation 
pressure (MPa); D, Drug solution flow rate (mL/min) 
a Ki = ∑(mean particle size at Ai)/4, the mean values of MPS for a certain factor at each level with 
standard deviation.  
b R = max Ki − min Ki. 
Table  2.  ANONA  analysis  of  four  parameters  for  SAS  micronization  of  
10-hydroxycamptothecin (HCPT). 
Source 
Sum of 
squares 
(SS) 
Degrees of 
freedom 
(df) 
F-ratio  F0.05 
Type of 
effect 
(A) Concentration of HCPT solution  182618.6  3  29.038  9.28  Significant 
(B) Precipitation temperature  154724  3  24.602  9.28  Significant 
(C) Precipitation pressure  117408.4  3  18.669  9.28  Significant 
(D) Drug solution flow rate  9585.187  3  1.524  9.28   
Error  6289.02  3       
3.2. Effect of Operating Conditions on the MPS of Micronized HCPT 
Analysis of variance showed that the concentration of HCPT solution, precipitation temperature and 
precipitation pressure had a significant effect on the MPS of  micronized HCPT (p < 0.05) in the 
selected ranges (Table 2). However, drug solution flow rate has no significant influence on the MPS.  
An orthogonal experimental design allows the separation of the effects of each individual factor 
investigated. However, it is interesting to analyze the effects of two factors on MPS. A nonlinear 
regression was applied using Design Expert 7.0 software to plot surface responses. The correlation 
related  the  MPS  of  micronized  HCPT  to  the  main  variables-concentration  of  HCPT  solution, 
precipitation temperature and precipitation pressure. 
Equation (1) is expressed as follows: 
2 2 2 4603 . 1 0640 . 0 4852 . 10 2973 . 0 6189 . 4 3836 . 0
6189 . 4 3836 . 0 5255 . 67 0994 . 8 1776 . 191 8459 . 915
C B A C B C A B A
C A B A C B A Y
              
            
  (1)  
Where Y is the MPS of micronized HCPT (nm), A is the concentration of HCPT solution (MPa), B 
is the precipitation temperature (°C ), and C is precipitation pressure (MPa). The correlation coefficient 
is 0.9591. Int. J. Mol. Sci. 2011, 12                       
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Figure 3 shows the three-dimensional response surfaces which were constructed to show the effects 
of the SAS process variables on MPS of micronized HCPT (Y). Figure 3a–c shows the interaction 
effect of precipitation temperature and concentration of HCPT solution, precipitation pressure and 
concentration of HCPT solution, and precipitation pressure and precipitation temperature on the MPS, 
respectively.  The  MPS  of  micronized  HCPT  was  found  to  increase  with  increasing  precipitation 
temperature and concentration of HCPT solution and decrease with increasing precipitation pressure.  
Figure 3. Response surface for MPS of micronized HCPT obtained by nonlinear regression. 
 
3.3. Morphology of Processed HCPT 
Figure 4 shows the SEM photomicrograph of original HCPT particles. As we can see, commercial 
HCPT particles are not uniform and basically pillar or bar shaped. The average particle size was found 
to be about 1 ×  1 ×  50 m. Figure 5a shows the SEM images of HCPT nanoparticles precipitated from 
DMSO under the optimum SAS process condition (0.5 mg/mL of concentration of HCPT solution,  
35 °C  of precipitation temperature, 20 MPa of precipitation pressure and 6.6 mL/min of HCPT solution 
flow rate), from which it is obvious that the HCPT nanoparticles are close to ellipsoidal with the MPS 
of 180 ±  20.3 nm and the particle size distribution (PSD) is shown in Figure 5b. 
Figure 4. Scanning electron microscope (SEM) image of unprocessed HCPT. 
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Figure 5. SEM image (a) and particle size distribution (PSD) (b) of HCPT nanoparticles.  
 
3.4. Physicochemical Properties of HCPT Nanoparticles 
3.4.1. FTIR Analysis 
We  performed  some  analysis  on  original  HCPT  particles  and  HCPT  nanoparticles  to  obtain 
information on the change of chemical structure after SAS processing. It can be seen that FTIR spectra 
between unprocessed and HCPT nanoparticles do not show any significant differences (Figure  6). 
Several  characteristic  IR  absorption  bands  and  their  assignments  are  shown  as  follows:  3494 and  
3346 cm
−1 (the O–H stretching mode), 3100–2750 cm
−1 (the C–H stretching vibration), 1723 cm
−1 
(C=O stretching vibration of lactone), 1653 cm
−1 (the C=O stretching vibration of amide), 1593 and 
1502 cm
−1 (the aromatic ring mode), 1266 and 1051 cm
−1 (the C–O and/or C–N stretching mode). 
Figure 6. FTIR spectra of unprocessed HCPTand HCPT nanoparticles. 
 
3.4.2. LC-MS Analysis 
The unprocessed and processed HCPT samples were evaluated by using LC-MS to determine the 
molecular weights, as shown in Figure 7. It can be seen that no modification occurred in molecular Int. J. Mol. Sci. 2011, 12                       
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weight  (364.5).  The  two  forms  exhibit  the  mass  spectral  peak,  at  365.5,  coming  from  the  
[C20H16N2O5 + H]
+ peak. This explains why there were no varieties about chemistry structure of HCPT 
before/after SAS process. Therefore, the SAS process has not induced degradation of HCPT. 
Figure 7. LC-MS spectra of the unprocessed HCPT (a) and HCPT nanoparticles (b). 
 
 
 
3.4.3. X-ray Analysis 
In order to further investigate particles, crystalline XRD analysis was performed. Figure 8 shows 
the XRD results for unprocessed HCPT particles and HCPT nanoparticles. The presence of several 
distinct peaks in the XRD of unprocessed HCPT at the diffraction angles of 2 = 13.821° , 11.659° , 
25.640° , 13.521° , 6.900° , 28.260° , 27.919°  and 27.219°  reveals that the drug is present as a crystalline 
form. On the other hand, HCPT nanoparticles were characterized by the complete absence of any 
diffraction peak corresponding to unprocessed HCPT. This fact suggests that HCPT particles after 
SAS  processing  are  no  longer  present  in  crystalline  form,  but  exist  in  the  amorphous  state.  Less 
crystalline smaller drug particles are higher in the dissolution rate or bioavailability than crystals and, 
thus, the therapeutic action is obtained in shorter times. Int. J. Mol. Sci. 2011, 12                       
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Figure 8. XRD patterns of the unprocessed HCPT and HCPT nanoparticles.  
 
3.4.4. DSC Analysis 
Figure 9 shows the DSC curves of unprocessed HCPT particles and HCPT nanopaticles. The DSC 
curves of unprocessed HCPT, a sharp endotherm at 279.93 °C  were observed. The sharp endotherm at 
279.93 °C  might be due to the melting point of HCPT. However, no endotherms were observed in the 
DSC  curves  for  HCPT  nanoparticles.  This  result  indicates  that  HCPT  is  no  longer  present  as  a 
crystalline form when processed using SAS, but exists in the amorphous state. 
Figure 9. DSC results of the unprocessed HCPT and HCPT nanoparticles. 
 
3.4.5. Dissolution Studies in Vitro 
Dissolution profiles of HCPT particles are shown in Figure 10. The HCPT nanoparticles showed a 
more rapid  dissolution  than the unprocessed  HCPT. After 120 min, the dissolution  rate of  HCPT 
nanoparticles and unprocessed HCPT were 85.89% and 7.64%, respectively. The HCPT nanoparticles 
had solubility eleven times higher than the unprocessed HCPT material. The dramatic increase in drug 
dissolution rate can be explained by the reduction of particle size resulting in an increased specific Int. J. Mol. Sci. 2011, 12                       
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surface area. The literature has also discussed how an increase in the amorphous content and porosity 
of the micronized drugs led to an enhanced dissolution rate [26]. 
Figure 10. Dissolution profiles of the unprocessed HCPT and HCPT nanoparticles. 
 
4. Conclusions  
In the present work, a process for micronization of HCPT by supercritical antisolvent (SAS) has 
been developed. Of the four factors that have an effect on SAS micronization of HCPT from DMSO, 
three  of  the  factors-concentration  of  HCPT  solution,  precipitation  temperature  and  precipitation 
pressure-have a significant effect on the MPS of micronized HCPT, while the drug solution flow rate 
showed  insignificant  effects.  The  optimum  micronization  conditions  are  as  follows:  35  °C   of 
precipitation temperature, 20 MPa of precipitation pressure, the flow rate ratio of CO2 and HCPT 
solution 19.55 and 0.5 mg/mL of HCPT solution concentration. Under the optimum conditions, HCPT 
nanoparticles with an MPS of 180 ±  20.3 nm were obtained. The characterization data of the HCPT 
nanoparticles using SEM, DLS, FTIR, LC-MS, XRD and DSC showed on one hand, no degradation of 
HCPT is induced by the SAS process, on the other hand, the obtained HCPT particles have lower 
crystallinity. Additionally, there is a great increase of dissolution rate in HCPT nanoparticles by the 
SAS process compared to unprocessed HCPT. In conclusion, the SAS process proposed in the study 
proved an efficient method for the preparation of HCPT nanoparticles. 
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